DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Rett syndrome — screening already-approved drugs against its 16-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleRett syndrome maps to a 16-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for rett syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
methyl-CpG binding protein 2 (MECP2) — MECP2 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet unxdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6OGK · 1.65 Å · ligand UNKNOWN ATOM OR ION (UNX). Experimental structure, not a prediction.
What the evidence adds up to
Rett syndrome is a neurodevelopmental disorder caused, in most cases, by mutations in the X-linked gene MECP2, leading to decreased MeCP2 protein levels. The syndrome is almost exclusively reported in girls and results in severe or profound developmental disabilities, with premature death occurring between ages 12 and 40 years. A 2024 clinical case report describes the use of main and additional diagnostic criteria alongside molecular genetic methods to confirm the mutation, but provides no data on any therapeutic intervention or outcome.
A 2017 review of patients who had Rett or Rett-like phenotypes but tested negative for mutations in MECP2, CDKL5, or FOXG1 found that whole exome sequencing revealed 69 different genes involved in epigenetic regulation, chromatin shaping, neurotransmitter action, or RNA transcription and translation. The review concludes that the Rett syndrome phenotype has a much broader underlying genetic cause and overlaps with other genetic disorders, and that both phenotype and genetic information are needed for proper counselling and treatment. No drug or treatment was tested in this review.
A 2012 paper describes Rett syndrome as a devastating and currently incurable neurodevelopmental disease caused by loss of MECP2, leading to developmental regression. It discusses the cellular and molecular contributions of MeCP2 overexpression to disease pathophysiology, but reports no clinical trial, no survival data, and no response rates for any intervention. No other abstracts provide evidence for any drug, treatment, or repurposing candidate. What remains missing is any controlled trial testing a specific drug in patients, any data on patient stratification by genetic subtype, and the funding to conduct such studies.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Current Opinion in Psychiatry · 2017 · 54 citations
Current developments in the genetics of Rett and Rett-like syndrome
AbstractPURPOSE OF REVIEW: This article reviews the current molecular genetic studies, which investigate the genetic causes of Rett syndrome or Rett-like phenotypes without a MECP2 mutation. RECENT FINDINGS: As next generation sequencing becomes broadly available, especially whole exome sequencing is used in clinical diagnosis of the genetic causes of a wide spectrum of intellectual disability, autism, and encephalopathies. Patients who were diagnosed with Rett syndrome or Rett-like syndrome because of their phenotype but were negative for mutations in the MECP2, CDKL5 or FOXG1 genes were subjected to whole exome sequencing and the results of the last few years revealed yet 69 different genes. Many of these genes are involved in epigenetic gene regulation, chromatin shaping, neurotransmitter action or RNA transcription/translation. Genetic data also allows to investigate the individual genetic background of an individual patient, which can modify the severity of a genetic disorder. SUMMARY: We conclude that the Rett syndrome phenotype has a much broader underlying genetic cause and the typical phenotype overlap with other genetic disorders. For proper genetic counselling, patient perspective and treatment it is important to include both phenotype and genetic information.
Journal of Neuroscience · 2012 · 5 citations · open access
Insights into the Cellular and Molecular Contributions of MeCP2 Overexpression to Disease Pathophysiology
AbstractRett syndrome (RTT) is a devastating and currently incurable neurodevelopmental disease that primarily affects females. RTT is caused by loss of the X-linked gene methyl-CpG-binding protein 2 ( MECP2 ). The resulting decreases in MeCP2 protein levels lead to symptoms such as developmental regression
Российский нейрохирургический журнал им профессора А Л Поленова · 2024 · 2 citations · open access
Rett syndrome: criteria for diagnosis, course, prognosis (description of a clinical case)
AbstractRett syndrome is a progressive neurodegenerative disease caused by a mutation in the MESP2 gene. To make a diagnosis, the main and additional criteria of the disease are used, as well as molecular genetic methods confirming the mutation. This article presents a clinical case of Rett syndrome, describes the main approaches to therapy and features of patient curation.
AbstractRett syndrome is a neurodevelopmental disorder which, in most cases, is caused by mutations in the X-linked gene MECP2 (Amir et al 1999). The syndrome is almost exclusively reported in girls and leads to severe or profound developmental disabilities and premature death aged 12 to 40 years (Akbarian and Worcester 2002, Neul et al 2010).
Characterizing the journey of Rett syndrome among females in the United States: a real-world evidence study using the Rett syndrome natural history study database
AbstractAbstract Background With the advent of the first targeted therapy for Rett Syndrome (RTT), a comprehensive assessment of the journey of RTT is needed to elucidate on present unmet needs in this population. This study characterized females with RTT in the United States and their disease journey with respect to longitudinal treatment patterns, RTT-related outcomes, and changes in disease severity. Methods This retrospective cohort study used registry data of females with RTT from the 5211 RTT Natural History Study (RNHS) (November 2015–July 2021). Pharmacological and supportive therapy use, RTT-related outcomes, and RTT severity, as measured by the Clinical Severity Scale and Motor Behavioral Assessment scale, were evaluated following the first RNHS visit. Analyses were conducted overall and in subgroups by RTT type (classic and atypical RTT) and age at first visit (pediatric and adult). Results A total of 455 females with RTT were included in the study, of whom 90.5% had classic RTT and 79.8% were pediatric individuals. Over a median follow-up of 4 years, use of pharmacological therapies, including prokinetic agents (42.7% vs. 28.3%), and supportive therapies, including physical therapy (87.3% vs. 40.2%) and speech-language therapy (86.8% vs. 23.9%), were more common in pediatric than adult individuals (all p < 0.05). Nearly half (44.6%) of all individuals had a hospital or emergency room visit, with a higher proportion of visits in individuals with classic RTT than atypical RTT and pediatric than adult individuals (both p = 0.001). An increasing trend in clinical severity was observed in pediatric individuals (mean change per year: 0.24; 95% confidence interval [CI]: 0.03, 0.44), while an increasing trend in motor-behavioral dysfunction was observed in pediatric individuals (mean change per year: 1.12; 95% CI: 0.63, 1.60) and those with classic RTT (mean change per year: 0.97; 95% CI: 0.53, 1.41). Conclusions Findings from this study highlight the considerable burden of RTT across disease subtype and age. Despite reliance on supportive therapies and healthcare encounters, individuals with RTT experience increasing disease severity and motor-behavioral dysfunction in childhood and adolescence, underscoring the unmet needs of this population and the value of early intervention to manage RTT in the long-term.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
